Erratum: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development (Cancer Cell (2010) 18(4) (367–381) (S1535610810003429) (10.1016/j.ccr.2010.09.005));Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development

Cancer Cell

Volumn 18, Issue 4, 2010, Pages 367-381

  Pichiorri, Flavia ^a,b   Suh, Sung Suk ^a,b   Rocci, Alberto ^c   De Luca, Luciana ^d   Taccioli, Cristian ^a,e   Santhanam, Ramasamy ^a   Zhou, Wenchao ^f   Benson, Don M ^g   Hofmainster, Craig ^g   Alder, Hansjuerg ^a   Garofalo, Michela ^a   Di Leva, Gianpiero ^a   Volinia, Stefano ^a,h   Lin, Huey Jen ^f   Perrotti, Danilo ^a   Kuehl, Michael ⁱ   Aqeilan, Rami I ^a,b   Palumbo, Antonio ^c   Croce, Carlo M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF TURIN   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f OHIO STATE UNIVERSITY   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h UNIVERSITY OF FERRARA   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MI 219; MICRORNA; MICRORNA 192; MICRORNA 194; MICRORNA 215; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; SOMATOMEDIN; UNCLASSIFIED DRUG; MDM2 PROTEIN, HUMAN; MESSENGER RNA; MUTAGENIC AGENT; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOREGULATION; BONE MARROW; CELL MIGRATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN REGULATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TREATMENT DURATION; ANIMAL; BIOLOGICAL MODEL; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; CHROMOSOME 11; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; METABOLISM; PATHOLOGY; PRECANCER; PROMOTER REGION; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 11; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICRORNAS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; MUTAGENS; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957936826     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.07.007     Document Type: Erratum

References (43)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
2. Braun C.J., Zhang X., Savelyeva I., Wolff S., Moll U.M., Schepeler T., Ørntoft T.F., Andersen C.L., Dobbelstein M. p53-Responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008, 68:10094-10104.
3. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., Mendell J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40:43-50.
4. Chng W.J., Glebov O., Bergsagel P.L., Kuehl W.M. Genetic events in the pathogenesis of multiple myeloma. Best Pract. Res. Clin. Haematol. 2007, 20:571-596.
5. Croce C.M. Oncogenes and cancer. N. Engl. J. Med. 2008, 358:502-511.
6. Danovi D., Meulmeester E., Pasini D., Migliorini D., Capra M., Frenk R., De Graaf P., Francoz S., Gasparini P., Gobbi A., et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell Biol. 2004, 24:5835-5843.
7. Dickens M.P., Fitzgerald R., Fischer P.M. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin. Cancer Biol. 2009, 20:10-18.
8. Fonseca R., Bergsagel P.L., Drach J., Shaughnessy J., Gutierrez N., Stewart A.K., Morgan G., Van Ness B., Chesi M., Minvielle S., et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23:2210-2221.
9. Froment P., Dupont J., Christophe-Marine J. Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle 2008, 7:3098-3103.
10. Galm O., Yoshikawa H., Esteller M., Osieka R., Herman J.G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2002, 101:2784-2788.
11. Garofalo M., Di Leva G., Romano G., Nuovo G., Suh S.S., Ngankeu A., Taccioli C., Pichiorri F., Alder H., Secchiero P., et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509.
12. Georges S.A., Biery M.C., Kim S.Y., Schelter J.M., Guo J., Chang A.N., Jackson A.L., Carleton M.O., Linsley P.S., Cleary M.A., et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res. 2008, 68:10105-10112.
13. Girnita L., Girnita A., Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 2003, 100:8247-8252.
14. Gutiérrez N.C., Sarasquete M.E., Misiewicz-Krzeminska I., Delgado M., De Las Rivas J., Ticona F.V., Fermiñán E., Martín-Jiménez P., Chillón C., Risueño A., et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010, 24:629-637.
15. He L., He X., Lowe S.W., Hannon G.J. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 2007, 7:819-822.
16. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17:193-199.
17. Hino K., Tsuchiya K., Fukao T., Kiga K., Okamoto R., Kanai T., Watanabe M. Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. RNA 2008, 14:1433-1442.
18. Junttila M.R., Evan G.I. p53-a Jack of all trades but master of none. Nat. Rev. Cancer 2009, 9:821-829.
19. Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., MacMenamin P., da Piedade I., Gunsalus K.C., Stoffel M., et al. Combinatorial microRNA target prediction. Nat. Genet. 2005, 37:495-500.
20. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2002, 2:175-187.
21. Lane D. How cells choose to die. Nature 2001, 414:25-27.
22. Lewis B.P., Shih I., Jones-Rhoades M., Bartel D., Burge C. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
23. Lionetti M., Biasiolo M., Agnelli L., Todoerti K., Mosca L., Fabris S., Sales G., Deliliers G.L., Bicciato S., Lombardi L., et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114:20-26.
24. Marine J.C., Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 2010, 17:93-102.
25. Miranda K.C., Huynh T., Tay Y., Ang Y.S., Tam W.L., Thomson A.M., Lim B., Rigoutsos I. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217.
26. Park S.Y., Lee J.H., Ha M., Nam J.W., Kim V.N. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat. Struct. Mol. Biol. 2009, 16:23-29.
27. Ooi M.G., Hayden P.J., Kotoula V., McMillin D.W., Charalambous E., Daskalaki E., Raje N.S., Munshi N.C., Chauhan D., Hideshima T., et al. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin. Cancer Res. 2009, 15:7153-7160.
28. Pichiorri F., Suh S.S., Ladetto M., Kuehl M., Palumbo T., Drandi D., Taccioli C., Zanesi N., Alder H., Hagan J.P., et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. USA. 2008, 105:12885-12890.
29. Qiang Y.W., Yao L., Tosato G., Rudikoff S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 2004, 103:301-308.
30. Quesnel B., Preudhomme C., Oscier D., Lepelley P., Collyn-d'Hooghe M., Facon T., Zandecki M., Fenaux P. Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br. J. Haematol. 1994, 88:415-418.
31. Roccaro A.M., Sacco A., Thompson B., Leleu X., Azab A.K., Azab F., Runnels J., Jia X., Ngo H.T., Melhem M.R., et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009, 113:6669-6680.
32. Saha M.N., Chang H. Pharmacological activation of the p53 pathway in haematological malignancies. J. Clin. Pathol. 2010, 63:204-209.
33. Shangary S., Qin D., McEachern D., Liu M., Miller R.S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 2008, 105:3933-3938.
34. Sinha A.U., Kaimal V., Chen J., Jegga A.G. Dissecting microregulation of a master regulatory network. BMC Genomics 2008, 23:88.
35. Song B., Wang Y., Kudo K., Gavin E.J., Xi Y., Ju J. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin. Cancer Res. 2008, 14:8080-8086.
36. Stuhmer T., Bargou R.C. Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies. Cell Cycle 2006, 5:39-42.
37. Tai Y.T., Podar K., Catley L., Tseng Y.H., Akiyama M., Shringarpure R., Burger R., Hideshima T., Chauhan D., Mitsiades N., et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res. 2003, 63:5850-5858.
38. Teoh G., Urashima M., Ogata A., Chauhan D., DeCaprio J.A., Treon S.P., Schlossman R.L., Anderson K.C. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 1997, 90:1982-1992.
39. Weiss B.M., Abadie J., Verma P., Howard R.S., Kuehl W.M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113:5418-5422.
40. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
41. Ventura A., Young A.G., Winslow M.M., Lintault L., Meissner A., Erkeland S.J., Newman J., Bronson R.T., Crowley D., Stone J.R., et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008, 132:875-886.
42. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
43. Zhang Y., Gao J.S., Tang X., Tucker L.D., Quesenberry P., Rigoutsos I., Ramratnam B. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett. 2009, 583:3725-3730.